2013 Fiscal Year Final Research Report
Resistance mechanisms of novel ALK inhibitors
| Project/Area Number |
24790798
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Keywords | ALK陽性肺癌 / アレクチニブ / 薬剤耐性 |
|---|
| Research Abstract |
Mechanisms of resistance with novel ALK tyrosine kinase, alectinib were investigated. H3122, EML4-ALK positive lung cancer cell line were treated with alectinib and showed resistance. These cell lines showed EGFR phosphorylation and MET signaling activation.
Combination therapy with EGFR tyrosine kinase inhibitor or MET inhibitor were effective for the treatment of H3122 alectinib resistance mouse xenograft model.
|
